GlobeNewswire

Bombardier Announces Organizational Changes

Share

Bombardier Inc. / Bombardier Announces Organizational Changes . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

MONTREAL, June 14, 2018 (GLOBE NEWSWIRE) -- Bombardier (TSX:BBD.B) today announced the following retirements and changes in responsibility for members of its Senior Leadership.

Effective immediately, Jim Vounassis is appointed Chief Operating Officer for Bombardier Transportation. Jim will report directly to Laurent Troger and join BT's core leadership team. He will have responsibility for BT's global operations, quality and procurement functions, as well as its overall industrial strategy. In this new position, Jim will focus on driving operational excellence and delighting customers with improved quality and delivery performance as we execute on our rail backlog of more than $35 billion.

"Jim is well suited for this role given his long track record of performance, including most recently leading Bombardier's Transformation and Procurement organizations, said Alain Bellemare, President and Chief Executive Officer, Bombardier Inc. "Jim's proven leadership ability and operational expertise will help accelerate BT's transformation efforts, securing its long-term competitive position in the fast growing global rail market."

A new organizational structure for the transformation and procurement organizations supporting Bombardier's aerospace units will be announced in the near future; until then Jim will maintain leadership responsibility.

"With the first half of our five-year turnaround plan successfully completed, Sylvain Lévesque has informed me of his desire to leave Bombardier and pursue the next chapter of his career, Bellemare explained. "I am extremely grateful for Sylvain's many contributions to Bombardier over the past 20 years, especially his strong leadership on many key initiatives, insights and sound counsel since I joined Bombardier. We will all miss the great camaraderie, and the extreme professionalism Sylvain has brought to our company."

Going forward, Louis Véronneau will assume responsibility for Bombardier's strategic planning process in addition to his current role overseeing Bombardier's partnerships, mergers, acquisitions and divestures as Bombardier's Senior Vice President, Strategy and Corporate Development.

"Louis is well qualified to assume this expanded role given his deep analytical skills, strong financial background and demonstrated leadership ability," Bellemare continued. "Louis spearheaded the negotiations for many of Bombardier's key strategic partnerships and divestitures, including the C Series partnership with Airbus and Investissement Québec, CDPQ's investment in Bombardier Transportation and Bombardier's sale of the Downsview property. With the company successfully de-risked, Louis will work closely with me and the rest of the leadership team to identify and execute strategic moves that support long-term sustainable growth across our portfolio."

"Finally, Nico Buchholz has advised me of his wish to retire later this summer," Bellemare explained.

Nico was recruited to join Bombardier in 2015 as Group Chief Procurement Officer and to support several other key projects including the C Series ramp-up. During his tenure at Bombardier, Nico achieved significant cost savings by establishing a more efficient and focused procurement organization, and successfully lead numerous other strategic initiatives and restructurings across the businesses.

"With the Airbus partnership effective on July 1, 2018 and his other projects drawing to a close, Nico has chosen to take on a new challenge. We are grateful for Nico's many important contributions to Bombardier, including his vision and leadership in supporting Bombardier's turnaround plan," Bellemare stated.

About Bombardier
With over 69,500 employees across four business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montreal, Canada, Bombardier has production and engineering sites in 28 countries across the segments of Transportation, Business Aircraft, Commercial Aircraft and Aerostructures and Engineering Services. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2017, Bombardier posted revenues of $16.2 billion US. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a trademark of Bombardier Inc.

For information
Simon Letendre
Manager, Media Relations and Public Affairs
Bombardier Inc.
+514 861 9481
 
Patrick Ghoche
Vice President, Investor Relations
Bombardier Inc.
+514 861 5727



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bombardier Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Incap’s Board of Directors resolved on a share-based incentive scheme for the company’s CEO26.5.2020 15:20:00 CESTPress release

Incap Corporation Stock Exchange Release 26 May 2020 at 4.20 p.m. (EEST) Incap’s Board of Directors resolved on a share-based incentive scheme for the company’s CEO Incap Corporation’s Board of Directors has resolved to implement a long-term share-based incentive scheme for the company’s CEO, Otto Pukk. The incentive scheme’s purpose is to support Incap’s strategy and incentivize the CEO in the effective implementation of the post-acquisition integration of AWS Electronics Group. The company has not previously had a share-based incentive scheme for CEO Otto Pukk. Any reward payable based on the incentive scheme is paid out entirely as Incap’s new shares. The earnings period for the CEO’s incentive scheme includes the ongoing and next financial period of the company so that it will end on 31 December 2021. During the earnings period, the CEO may earn a performance-based reward amounting up to 5,730 new shares of the company based on the development of the company’s EBIT provided that th

USD TENDER OPERATION ANNOUNCEMENT26.5.2020 15:00:00 CESTPress release

USD TENDER OPERATION ANNOUNCEMENT MAY-28-2020 Transaction type: Reverse TransactionOperation type:Liquidity providingTender date:MAY-28-2020Time for submission of bids14.00-14.30 (CEST)Start date:JUN-1-2020Maturity date:AUG-24-2020Duration:84 daysOffered volume:10.0 bln Min bid amount: 100 mlnMaximum bid amount: 4.0 blnMax number of bids:10Lowest interest supplement:0.25 percentage pointsMin bid rate:t.b.a.Allocation time:15.00 (CEST) on Tender date Approved counterparties are invited to submit bids to the Riksbank, tel +46 8 6966970 by 14.30 (CEST) pm on May 28, 2020. Confirmation of bids to e-mail: https://www.globenewswire.com/Tracker?data=m3O1JLVEmyGluQh0AvJvGpAt6AU1L2Qmmo7-ktvXU5fV3d13DU2X3whKS1qawLrAoNyGIVGKywGQ1AWND3wnpA== eol@riksbank.se

Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CESTPressemelding

Den 2 juni kl 14.00 presenterar​ ​Henrik Nittmar, VD i Corline Biomedical AB​ den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020​ där presentationen även i efterhand kommer finnas tillgänglig, s​amt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati

Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CESTPressemelding

Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: henrik.nittmar@corline.se Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: ca@skmg.se Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare

Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CESTPress release

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta

PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CESTPress release

Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757